Patrick Campbell

Philip Mease, MD, director of rheumatology research at the Swedish Rheumatology Research Group, discusses the current state of treatments for psoriatic arthritis.

Elaine Husni, MD, discusses the results of a trial she led examining quality of life changes in psoriatic arthritis patients receiving golimumab over a 1-year period.

John Sundy, MD, PhD, senior vice president of Inflammation and Respiratory Disease with Gilead Sciences, discusses the results of a pooled safety analysis examining phase 3 studies of filgotinib.

Raymond Douglas, MD, PhD, discusses teprotumumab and its potential for treating thyroid eye disease.

Peter Izmirly, MD, discusses the results of a trial he led examining the possible reduction in recurrence of congenital heart block from treatment with hydroxychloroquine at ACR 2019.

Renowned infectious disease expert Leonard Calabrese, DO, professor of medicine at the Cleveland Clinic Lerner College of Medicine, takes part in a Q&A on vaccinations in immunocompromised patient populations.

Aileen Pangan, MD, executive medical director of Immunology with AbbVie, discusses the results of the SELECT-AXIS 1 trial and what it indicates about upadacitinib as a treatment for ankylosing spondylitis.

Jianmin Fang, PhD, CEO and founder of Remegen Ltd., discusses the results of a phase 2b trial exmaining the use of telitacicept for the treatment of SLE.

Yusuf Yazici, MD, chief medical officer of Samumed, discusses SM04690(Lorecivivint) at ACR 2019.

John Sundy, MD, PhD, senior vice president of Inflammation and Respiratory Disease with Gilead Sciences, discusses the results of the 156-week analysis of filgotinib in RA patients.

Philip Mease, MD, Director of Rheumatology Research at the Swedish Rheumatology Research Group, discusses why he believes some rheumatologists are skeptical of JAK inhibitors and where they fit in current treatment algorithms.

Martin Bergman, MD, clinical associate professor of Medicine at Drexel University, discusses the results of a study examining prevalence of burnout among rheumatologists.

Full 52-week results of the SPIRT-H2H trial were presented during the late breaking session at ACR 2019.

Brian LaMoreaux, MD, medical director with Horizon Therapeutics, discusses response to concurrent methotrexate and pegloticase use for treating uncontrolled gout.

Deodhar discusses the results of a study comparing the symptoms and treatment patterns in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.

Philip Mease, MD, Director of Rheumatology Research at Swedish Rheumatology Research Group, reflects upon new data and discusses where he sees guselkumab fitting into a PsA patient's current treatment plan.

A new study from ACR 2019 found tocilizumab outperformed rituximab in rheumatoid arthritis patients with low B-cell levels.

Daniel Clauw, MD, of the University of Michigan, discusses how the diagnosis of a rheumatic condition can impact the mental health of patients.

Jeffrey Curtis, MD, discusses how the Vectra test can be a useful tool for rheumatologists at ACR 2019.

An analysis of more than 7000 patients presented at ACR 2019 found there was no significant differences in safety or efficacy of biologic DMARDs based on the age of RA onset.

Elaine Husni, MD, discusses how she goes about choosing which therapy is most appropriate for a patient with psoriatic arthritis.

Daniel Clauw, MD, of the University of Michigan, discusses the impact public perception has had on pain management practices for patients with rheumatic diseases and chronic pain.

Using the largest SLE birth cohort ever established, investigators determined children exposed to non-TNF inhibitors in utero were at a low risk of serious infection.

A 19-year analysis presented at ACR 2019 has found opioid use disorder hospitalizations among some rheumatic diseases have increased more than 30-fold since 1998.

Jeffrey Curtis, MD, discusses the results of a study he led examining the safety of the zoster vaccine in immunocompromised populations, specifically patienta with rheumatic diseases receiving TNF inhibitors.

Patients with lupus were at an increased risk of 30-day all-cause mortality following coronary revascularization when compared to patients with diabetes mellitus and the general population.

A new study presented at ACR 2019 is debunking the notion that use of ultrasound to guide treatment in early rheumatoid arthritis provides added benefit over conventional treatment strategies.

A new study has found use of methotrexate could reduce joint damage progression and facilitate bone remodeling in patients with hand osteoarthritis.

A new study presented at ACR 2019 has found spending on bDMARDs nearly doubled between 2012 and 2016, with post-market drug price changes driving most of the increase.

New 2020 osteoarthritis guidelines, developed by the American College of Rheumatology and the Arthritis Foundation, were previewed during ACR 2019.